Cencora (COR): financials, SEC filings and peers
Cencora (COR) is a health care distributors company in the Health Care sector of the S&P 500, headquartered in Conshohocken, Pennsylvania.
It was founded in 1985 and joined the S&P 500 on August 30, 2001.
Its fiscal year ends in September, and its shares trade on the NYSE.
In its SEC filings it is classified as “Wholesale-Drugs, Proprietaries & Druggists' Sundries”.
Cencora at a glance
- Revenue (12 months)
- $332.8B
- Revenue growth
- +5.1%
- Operating margin
- 0.9%
- Net income (12 months)
- $2.6B
- Free cash flow (12 months)
- $4.1B
- Cash
- $2.8B
- Debt
- $11.7B
- Diluted EPS (12 months)
- $13.47
Twelve months to June 30, 2026, from the 10-Q filed August 5, 2026.
Latest twelve months
Over the twelve months to June 30, 2026, Cencora reported revenue of $332.8 billion, about the same as a year earlier (+5.1%).
Its operating margin was 0.9%: for every $100 of sales, about $1 was left as operating profit.
Net income was $2.6 billion (0.8% of revenue), 38.3% higher than a year earlier.
Operating cash flow was $4.8 billion and capital spending $761 million, leaving free cash flow of $4.1 billion (1.2% of revenue).
At the end of the period it held $2.8 billion in cash and $11.7 billion in debt, a net debt position of $8.9 billion.
Five-year trend
- Revenue went from $189.9 billion in fiscal 2020 to $321.3 billion in fiscal 2025, about 11.1% a year.
- Revenue has grown for 5 fiscal years in a row.
- Operating margin widened from -2.7% to 0.8% over the same years.
- Free cash flow was positive in each of the last 6 fiscal years.
- Cencora reported a net loss in 1 of the last 6 fiscal years.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $214.0B | $238.6B | $262.2B | $294.0B | $321.3B |
| Revenue growth | 12.7% | 11.5% | 9.9% | 12.1% | 9.3% |
| Operating margin | 1.1% | 1.0% | 0.9% | 0.7% | 0.8% |
| Net income | $1.5B | $1.7B | $1.7B | $1.5B | $1.6B |
| Free cash flow | $2.2B | $2.2B | $3.5B | $3.0B | $3.2B |
| Diluted EPS | $7.39 | $8.04 | $8.53 | $7.53 | $7.96 |
Fiscal years as reported in Cencora’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 8-K filed September 25, 2026 — Executive or director change; Regulation FD disclosure
- 8-K filed August 14, 2026 — Executive or director change
- 8-K filed August 12, 2026 — Regulation FD disclosure
- 10-Q filed August 5, 2026 — quarterly report
- 8-K filed August 5, 2026 — Material agreement; New debt obligation
- 8-K filed August 5, 2026 — Earnings results; Regulation FD disclosure
- 8-K filed June 15, 2026 — Executive or director change; Regulation FD disclosure
- 8-K filed May 29, 2026 — Executive or director change; Regulation FD disclosure
Companies like Cencora
Other S&P 500 companies in Health Care Distributors:
- CAHCardinal HealthDublin, Ohio
- HSICHenry ScheinMelville, New York
- MCKMcKesson CorporationIrving, Texas
More from Health Care
Questions about Cencora
Is Cencora's revenue growing?
Yes. Revenue for the twelve months to June 30, 2026 was $332.8 billion, up 5.1% from a year earlier, according to its SEC filings.
Is Cencora profitable?
Yes. It earned $2.6 billion in net income over the twelve months to June 30, 2026, a net margin of 0.8%.
Does Cencora have more cash or more debt?
At June 30, 2026 it had $2.8 billion in cash and $11.7 billion in debt, so more debt than cash.
When did Cencora last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on August 5, 2026.
Which companies are similar to Cencora?
In the S&P 500, Cencora is grouped in Health Care Distributors within the Health Care sector. Cardinal Health (CAH), Henry Schein (HSIC), McKesson Corporation (MCK) are in the same group.
Understand the numbers
Source: Cencora’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.